Antonella Lavagetto

Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.

Antonio Piga, Renzo Galanello, Maria Domenica Cappellini et al. · PubMed · 2006 · 269 citations · Full text

Medicine, Hematology, Pharmacology +17

Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.

Renzo Galanello, Antonio Piga, Yves Bertrand et al. · PubMed · 2006 · 139 citations

Medicine, Hematology, Pharmacology +17

Growth in patients after allogeneic bone marrow transplant for hematological diseases in childhood.

A Cohen, C Uderzo, Attilio Rovelli et al. · PubMed · 1995 · 25 citations

Medicine, Hematology, Pediatrics +14

Once-Daily Treatment with the Oral Iron Chelator ICL670 (Exjade®): Results of a Phase II Study in Pediatric Patients with β-Thalassemia Major.

Antonio Piga, Renzo Galanello, Maria Loreta Foschini et al. · Blood · 2004 · 15 citations

Medicine, Hematology, Pediatrics +16

Non-Invasive Measurement of Iron Overload in the Human Body

M. Marinelli, S. Cuneo, Barbara Gianesin et al. · IEEE Transactions on Applied Superconductivity · 2006 · 14 citations

Medicine, Biological Engineering, Hematology +15